SCHEMBL5863364

SCHEMBL5863364

CCOC(=O)c1ccccc1-c1cccc(CSCCO)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
SCN1A P35498 2/20 0.44
SCN2A Q99250 2/20 0.44
SCN3A Q9NY46 2/20 0.44
ERN1 O75460 1/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 2/20 0.42
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPK10 P53779 1/20 0.42
KMT2A Q03164 1/20 0.42
PTK2B Q14289 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863068 0.88 TSHR (0.50) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL5863103 0.86 SMN1; SMN2 (0.45) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL5863053 0.82 CYP4F2 (0.55) ALDH1A1SMN1; SMN2MAPTHPGDRAB9A
SCHEMBL5863075 0.81 BCL2 (0.49) SMN1; SMN2MEN1KMT2ARAB9ACA2
SCHEMBL5863077 0.80 CYP4F2 (0.53) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL27686775 0.80 TSHR (0.59) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL5863151 0.79 TSHR (0.51) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL396552 0.78 TSHR (0.69) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL3947570 0.77 TSHR (0.59) TSHRSCN1ASCN2ASCN3AERN1
SCHEMBL5863108 0.77 CYP4F2 (0.46) ALDH1A1SMN1; SMN2MAPTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132456-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2006-11-07 US disclosed
US-20060052449-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2006-03-09 US disclosed
EP-1572637-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-09-14 EP disclosed
WO-2004052848-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052449-A1 Novel mch receptor antagonists MCHR1, MCHR2, MC1R TSHR 107/4885SCN1A 1284/4885SCN2A 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.